Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy

Capricor Therapeutics, which received early funding from CureDuchenne, has shared news of positive interactions with the FDA for their CAP-1002 program for DMD.  Capricor will be having an additional meeting with the FDA in Q2 2024, where they will share data and discuss the plan for submitting a rolling BLA, which might expedite their path to potential drug approval. 


Read the Full Press Release HERE